"GLP-1 medications are creating tremendous upheaval for employers and payers, and our new contract is a great example of how Dario is helping employers address the growing and costly problem," said Rick Anderson, president of Dario. "Dario's solutions have been proven, in prior studies, to deliver long-term behavior change with and without a GLP-1 medication to help employers realize the full potential in health outcomes." To view the full press release, visit https://ibn.fm/3Oh8j About DarioHealth Corp. DarioHealth is a leading digital health company, revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Its platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.